Transverse Myelitis Trial, Recruiting NCT05566769 Sponsor: Ad scientiam Condition: Transverse Myelitis
Back to Transverse Myelitis

Transverse Myelitis Trial, Recruiting

NCT05566769
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You have been diagnosed with Neuromyelitis Optica Spectrum Disorder (NMOSD) that has tested positive for a specific protein marker called AQP4, based on 2015 international diagnostic guidelines
  • You are already receiving treatment for NMOSD, and your treatment has not changed in the last 6 months (or in the last 1 month for pain relief, antidepressant, or antipsychotic medications)
  • Your level of disability, as measured by a standard neurological scale, is at or below a certain threshold (confirm with trial site)
  • You have not had a relapse or worsening of your condition in the 3 months before joining the trial
  • You have read and signed a consent form agreeing to take part
  • You are able to use a smartphone
  • You own a personal smartphone running iOS version 13 or higher, or Android version 8 or higher
  • You are able to read the language the mobile app is available in and can understand simple picture-based symbols

Who may not be able to join:

  • You have another neurological, joint/muscle, or mental health condition (other than NMOSD) — such as a major head injury, seizures, or a serious ongoing illness — that could affect your thinking, arm, or leg function
  • You are currently pregnant or breastfeeding
  • You are under a legal guardianship arrangement that limits your ability to make your own decisions
  • You are bedridden or active for less than 2 hours per day
  • You currently misuse drugs or alcohol in a way that could affect your test results, based on a doctor's assessment
  • You have taken part in another clinical trial within the past 30 days, or are currently in another trial that might interfere with this one

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 617-726-7565

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Ad scientiam
Registry
ClinicalTrials.gov
Start date
3 November 2023
Est. completion
1 September 2025

Where this trial is recruiting

🇫🇷 France 🇩🇪 Germany 🇺🇸 United States

Primary endpoints

To compare results obtained with unsupervised at-home e-active tests and the corresponding supervised in-clinic standard tests, test to test

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov